La cadena de opciones muestra datos clave de las opciones de acciones de CureVac a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para CureVac..

CureVac (NASDAQ:CVAC) Bolsa, Cadena de Opciones

CureVac

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

Large Cap

News

Health Care

General

CVAC

MRNA

NVAX

Un trabajador lechero en Nevada da positivo en gripe aviar H5N1. CDC investiga mientras la cepa se propaga en aves y ganado.

Gripe aviar en EE.UU.: trabajador lechero en Nevada da positivo

CureVac NV

B of A Securities analyst Jason Gerberry maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and raises the price target from $143 to $167.

Price Target

Analyst Ratings

AXSM

B of A Securities Maintains Buy on Axsome Therapeutics, Raises Price Target to $167

B of A Securities analyst Michael McGovern maintains Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) with a Buy and raises the price target from $19 to $21.

LYFT

B of A Securities Maintains Buy on Lyft, Raises Price Target to $21

B of A Securities analyst Sara Senatore maintains McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) with a Neutral and raises the price target from $312 to $316.

B of A Securities Maintains Neutral on McDonald's, Raises Price Target to $316

Texas Roadhouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) has outperformed the market over the past 10 years by 6.25% on an annualized basis producing an average annual return of 17.41%. Currently, Texas Roadhouse has a market capitalization of $11.54 billion. 
Buying $100 In TXRH: If an investor had bought $100 of TXRH stock 10 years ago, it would be worth $497.60 today based on a price of $173.05 for TXRH at the time of writing.
<h3>Texas Roadhouse's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739284362_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

TXRH

$100 Invested In Texas Roadhouse 10 Years Ago Would Be Worth This Much Today

STAI

ScanTech AI Management Confirms Company Has No Convertible Or Variable Rate Indebtedness And No Dilutive Equity Structure On Balance Sheet

B of A Securities analyst Robert Ohmes maintains Sprouts Farmers Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) with a Buy and raises the price target from $165 to $185.

B of A Securities Maintains Buy on Sprouts Farmers Market, Raises Price Target to $185

Barclays analyst Ryan Macwilliams maintains Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) with a Overweight and raises the price target from $325 to $360.

MNDY

Barclays Maintains Overweight on Monday.Com, Raises Price Target to $360

Macro Economic Events

Economics

Federal Reserve

Fed's Hammack Says Federal Government Debt Is On Unsustainable Path Over Longer Term; Rate Hike Is Not In My Base Case, Economy In Good Position; Unclear How Much 2024 Rate Cuts Have Factored Into; We May Be Close To Neutral Rate

Biotech

Government

Regulations

BBIO

BEYONTTRA Receives European Commission Marketing Authorization For BEYONTTRA For Treatment Of ATTR-CM

B of A Securities analyst Steve Byrne maintains Bunge Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) with a Buy and lowers the price target from $105 to $87.

B of A Securities Maintains Buy on Bunge Global, Lowers Price Target to $87

Barclays analyst Tim Long maintains Harmonic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) with a Equal-Weight and lowers the price target from $14 to $10.

HLIT

Barclays Maintains Equal-Weight on Harmonic, Lowers Price Target to $10

Contracts

ESEA

Euroseas Announces 2-Year Charter Contract Extension For Feeder Containership, M/V EM Hydra; For Minimum Period Of 24 Months And Maximum Period Of 26 Months At Gross Daily Rate Of $19,000

B of A Securities analyst Michael Cherny maintains Progyny (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>) with a Buy and raises the price target from $21 to $25.

PGNY

B of A Securities Maintains Buy on Progyny, Raises Price Target to $25

B of A Securities analyst Salvator Tiano maintains Archer-Daniels Midland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) with a Underperform and lowers the price target from $54 to $48.

B of A Securities Maintains Underperform on Archer-Daniels Midland, Lowers Price Target to $48

Results demonstrate that CELZ-201 achieved an 80% overall efficacy rate in reducing insulin dependency and stabilizing hemoglobin A1c levels, with no serious adverse effects reported.

CELZ

Creative Medical Technology Reports One-Year Results For AlloStem Type 2 Diabetes Program

Fed's Hammack Says Will Evaluate Trump Economic And Trade Policies As They Come In

Barclays analyst Dan Levy maintains BorgWarner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) with a Overweight and lowers the price target from $43 to $42.

Barclays Maintains Overweight on BorgWarner, Lowers Price Target to $42

B of A Securities analyst Steve Byrne maintains Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) with a Buy and raises the price target from $69 to $73.

CTVA

B of A Securities Maintains Buy on Corteva, Raises Price Target to $73

As of Feb. 11, 2025, two stocks in the real estate sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Zillow Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>)</h3>
<ul>
<li>On Feb. 5, Benchmark analyst Daniel Kurnos maintained Zillow with a Buy and raised the price target from $80 to $100. The company's stock gained around 25% over the past month and has a <a href="https://www.benzinga.com/quote/ZG">52-week high of $85.89</a>.</li>
<li>RSI Value: 75&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>ZG Price Action: Shares of Zillow gained 1% to close at $85.29 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Welltower Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>)</h3>
<ul>
<li>On Jan. 29, NorthStar Healthcare Income, Inc. agreed to be acquired by an affiliate of Welltower for $3.03 per share in a $900 million transaction. Nikhil Chaudhri, Co-President and Chief Investment Officer of Welltower said, &#8220;We are delighted to have reached an agreement to acquire NorthStar&#8217;s portfolio of 40 seniors housing communities, which portfolio, subject to satisfaction of closing conditions and closing under the merger agreement, Welltower anticipates will be allocated to an entity affiliated with its recently announced funds management business." The company's stock gained around 14% over the past month and <a href="https://www.benzinga.com/quote/WELL">has a 52-week high</a> of $143.84.</li>
<li>RSI Value: 70.8</li>
<li>WELL Price Action: Shares of Welltower gained 0.4% to close at $143.11 on Monday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43593480/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-with-over-6-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks With Over 6% Dividend Yields</a></li>
</ul>

Short Ideas

Pre-Market Outlook

Markets

WELL

Top 2 Real Estate Stocks You May Want To Dump In February

WIIM

WESCO shares are trading lower following a Q4 EPS miss.

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company's shares closed yes...

Leerink Partners Sticks to Their Hold Rating for CureVac (CVAC)

Analyst Roy Buchanan of JMP Securities reiterated a Buy rating on CureVac (CVAC – Research Report), retaining the price target of $16.00. Roy Bucha...

CureVac: Strong Financial Position and Promising Pipeline Justify Buy Rating

California Gov. Newsom declares State of Emergency over bird flu

Vaccine stocks gain amid uptick in flu, COVID-19, RSV

Bird flu claims first U.S. life in Louisiana

Shares of Moderna (MRNA), one of a few drugmakers currently developing a vaccine for the H5N1 bird flu, were up nearly 10% in early trading after t...

Bird flu vaccine maker Moderna shares jump after first US death, Barron's says

Moderna, Novavax and other vaccine names extend gains amid COVID/flu concerns

Arbutus could benefit from Big Pharma bird flu vaccines: Jefferies

CureVac: Latest GBM Data Bodes Well For Next Program Check Point

Bird flu reaches NYC as live poultry markets shut down

ABUS

ARCT

BNTX

CSLLY

GLAXF

ROIV

Press Releases

CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

Earnings

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza  mRNA Vaccine Program

CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

Events

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

CureVac to Present at the 12th International mRNA Health Conference

Management

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

JMP Securities

Leerink Partners

B of A Securities

SVB Securities

Comments

CureVac

CureVac (CVAC) Opciones

CureVac (NASDAQ:CVAC) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL